
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
Click the title above for a link to open the Applied Clinical Trials February 2025 issue in an interactive PDF format.
almost 2 years ago
Prioritizing Efficiencyalmost 2 years ago
Replacing Anecdotal With Empirical Evidence On Impact of DCTsalmost 2 years ago
In Focus: The Top Needs in a Clinical Trials Software Packagealmost 2 years ago
The Transformative Power of Data Analytics in Clinical Trialsalmost 2 years ago
The Federal Research Credit: Is It Worth All the Trouble?almost 2 years ago
Benchmarking the Investigative Site Qualification Processalmost 2 years ago
Data Collection in Clinical Trials with Multiple Caregiversalmost 2 years ago
Embracing Change and Intentionally Living ‘a Life of Why’





